Search | Search by Center | Search by Source | Keywords in Title
Sinha A, Rajan M, Hoerger T, Pogach L. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. Diabetes Care. 2010 Apr 1; 33(4):695-700.
Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects. Exenatide and sitagliptin may confer substantial costs to health care systems. Demonstrated gains in quality and/or quantity of life are necessary for these agents to provide economic value to patients and health care systems.